AbbVie (NYSE:ABBV – Free Report) had its price objective increased by Barclays from $325.00 to $335.00 in a report published on Monday morning,Benzinga reports. They currently have an overweight rating on the stock.
Other research analysts have also recently issued research reports about the company. Leerink Partners raised their target price on AbbVie from $309.00 to $342.00 and gave the company an “outperform” rating in a research note on Monday, November 2nd. Rothschild & Co Redburn upped their target price on shares of AbbVie from $284.00 to $285.00 and gave the stock a “buy” rating in a research note on Tuesday, August 4th. BNP Paribas Exane increased their price objective on AbbVie from $218.00 to $247.00 and gave the company a “neutral” rating in a research report on Tuesday, August 11th. The Goldman Sachs Group lifted their target price on shares of AbbVie from $258.00 to $294.00 and gave the stock a “neutral” rating in a research report on Friday, October 23rd. Finally, Wolfe Research upgraded AbbVie from a “peer perform” rating to an “outperform” rating and boosted their price target for the company from $235.00 to $300.00 in a research note on Thursday, August 13th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $299.62.
View Our Latest Report on ABBV
AbbVie Trading Down 2.4%
Shares of NYSE:ABBV opened at $285.92 on Monday. The company has a 50-day moving average price of $277.84 and a 200-day moving average price of $241.96. The company has a market cap of $505.39 billion, a price-to-earnings ratio of 22.82, a price-to-earnings-growth ratio of 1.33 and a beta of 0.20. AbbVie has a 12 month low of $190.75 and a 12 month high of $302.93.
AbbVie (NYSE:ABBV – Get Free Report) last released its quarterly earnings data on Friday, October 30th. The company reported $3.82 earnings per share for the quarter, topping the consensus estimate of $3.73 by $0.09. AbbVie had a negative return on equity of 450.55% and a net margin of 15.67%. The business had revenue of $17.40 billion during the quarter, compared to analysts’ expectations of $17.32 billion. During the same quarter last year, the business posted $1.86 EPS. The business’s revenue was up 10.3% on a year-over-year basis. As a group, research analysts forecast that AbbVie will post 13.98 EPS for the current fiscal year.
AbbVie Increases Dividend
The business also recently declared a quarterly dividend, which will be paid on Tuesday, February 16th. Shareholders of record on Friday, January 15th will be issued a $1.82 dividend. The ex-dividend date is Friday, January 15th. This represents a $7.28 dividend on an annualized basis and a yield of 2.5%. This is an increase from AbbVie’s previous quarterly dividend of $1.73. AbbVie’s payout ratio is presently 119.10%.
Insider Activity
In related news, EVP Jeffrey Stewart sold 40,619 shares of the business’s stock in a transaction dated Monday, November 9th. The stock was sold at an average price of $293.60, for a total value of $11,925,738.40. Following the sale, the executive vice president directly owned 83,171 shares in the company, valued at approximately $24,419,005.60. The trade was a 32.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.06% of the company’s stock.
Institutional Investors Weigh In On AbbVie
Several large investors have recently bought and sold shares of ABBV. State Street Corp raised its position in AbbVie by 0.3% during the third quarter. State Street Corp now owns 82,815,387 shares of the company’s stock valued at $21,663,677,000 after purchasing an additional 218,639 shares during the period. Fisher Asset Management LLC lifted its position in shares of AbbVie by 252.6% during the third quarter. Fisher Asset Management LLC now owns 33,489,421 shares of the company’s stock worth $8,760,498,000 after purchasing an additional 23,991,451 shares during the last quarter. Corient Private Wealth LP bought a new stake in AbbVie during the 2nd quarter valued at about $559,736,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of AbbVie by 0.7% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,267,697 shares of the company’s stock valued at $3,590,323,000 after acquiring an additional 106,091 shares in the last quarter. Finally, Legal & General Group Plc bought a new stake in AbbVie during the 2nd quarter valued at $2,905,952,000. Institutional investors own 70.23% of the company’s stock.
Key AbbVie News
Investors following ABBV have been watching these news items:
- Positive Sentiment: Barclays raised its price target to $335 from $325 and maintained an Overweight rating, citing continued upside potential. AbbVie Is Up 27% in a Year. Barclays Sees Another 14%
- Positive Sentiment: AbbVie’s neuroscience franchise grew operational sales 19.5% in the third quarter, and the company lifted its 2026 sales outlook for the segment to $13 billion—evidence of momentum beyond its established medicines. How Did AbbVie’s Neuroscience Franchise Perform in Q3?
- Positive Sentiment: AbbVie reported an update on its Phase 2b/3 study of ABBV-2294 for systemic sclerosis, a rare condition. Progress in the trial could expand the company’s pipeline, though the report does not provide efficacy results. AbbVie Advances ABBV-2294 Study for Rare Systemic Sclerosis
About AbbVie
AbbVie is a biopharmaceutical company that discovers, develops and markets medicines for a range of serious health conditions. Its research and product portfolio spans immunology, oncology, neuroscience and other therapeutic areas. Key products include the immunology medicines Skyrizi and Rinvoq, cancer treatments such as Imbruvica and Venclexta, and neuroscience therapies including Botox and Vraylar. Through its Allergan acquisition, AbbVie also offers aesthetics products such as Botox Cosmetic and Juvéderm.
Further Reading
- Five stocks we like better than AbbVie
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
